Allarity Therapeutics, Inc. develops personalized cancer treatments as a clinical-stage biopharmaceutical company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and its DRP® companion diagnostic technology. The company’s updates center on Phase 2 oncology development, advanced ovarian cancer, clinical and scientific data presentations, companion-diagnostic intellectual property, FDA Fast Track status, and potential use of stenoparib in additional tumor settings.
Recurring news also covers operating and financial results, financing activity that supports clinical programs, research collaborations, and governance matters for the Nasdaq-listed company.
Allarity Therapeutics (NASDAQ: ALLR) reported recent patent awards and laboratory certification supporting its Drug Response Predictor technology for stenoparib’s clinical development. The predictor, or DRP, uses tumor gene expression to help select patients who may respond to treatment. At AACR 2026, an exploratory analysis of a prior Phase 2 cohort with advanced ovarian cancer found that higher pretreatment DRP scores were associated with longer overall survival following twice-daily stenoparib.
Recent patent awards and CLIA certification of Allarity’s in-house laboratory allow it to extend the test’s use as a companion diagnostic and retain sole control of the clinical test. Allarity plans to use DRP to inform patient selection for a pivotal trial toward potential FDA approval. Stenoparib remains its principal development focus, while its experience developing predictors for other drugs provides a foundation for potential external partnerships.
Allarity Therapeutics (ALLR) expanded its in-house medical laboratory to include proteomics and cell line research for stenoparib.
The additions build on existing transcriptomics research and CLIA clinical testing services. The laboratory’s nCounter Pro instrument can now use a protein panel that measures approximately 300 targets. Allarity expects the expanded capabilities to support research into how stenoparib works and broaden the services it can offer existing and prospective customers. The expansion will not affect its current cash runway and may generate cost efficiencies by allowing more research in-house.
Allarity Therapeutics (ALLR) received a Japanese patent for its stenoparib-specific DRP® companion diagnostic, providing protection in Japan until 2039. The patent (Japanese Patent No. 7917283) covers methods for using gene-expression profiles from tumor samples to predict which patients are most likely to benefit from stenoparib treatment and to select them via the stenoparib DRP® test.
Allarity already holds stenoparib DRP® patents in the United States, with protection into April 2042, as well as in certain European jurisdictions and Australia, with additional applications pending globally. Stenoparib, a dual PARP/tankyrase inhibitor targeting PARP1/2 and WNT-related tankyrase 1/2, is in Phase 2 development for advanced and platinum-resistant ovarian cancer, and is also being studied in combination with temozolomide for relapsed small cell lung cancer.
Allarity Therapeutics (ALLR) has sponsored Allarity Acquisition Corp., a newly formed SPAC that has filed a Form S‑1 registration statement with the SEC for a proposed initial public offering of its units, with an expected base offering size of $100 million, or $115 million if the underwriters fully exercise their over‑allotment option.
ALLR Sponsor LLC, a wholly owned subsidiary of Allarity, is the sponsor of the SPAC and is expected to own approximately 25.0% of its issued and outstanding ordinary shares after the offering, subject to the Registration Statement terms. The SPAC may pursue a business combination in any industry or region and has applied to list its units on Nasdaq under “ALLNU,” with Class A ordinary shares and warrants expected to trade separately as “ALLN” and “ALLNW” after unit separation. Allarity stated that this transaction does not change its expectation that existing working capital will fund operations into the summer of 2028. The registration statement is preliminary and not yet effective, and no securities may be sold until it becomes effective.
Allarity Therapeutics (NASDAQ: ALLR) reported second quarter 2026 results and key stenoparib milestones. As of June 30, 2026, cash and restricted cash totaled $26.9 million versus $14.7 million a year earlier, with operating cash use of $2.6 million in the quarter. R&D and G&A expenses declined to $1.3 million each, narrowing total comprehensive loss to $3.7 million from $4.2 million.
The USPTO granted a key U.S. patent protecting the stenoparib-specific DRP companion diagnostic into April 2042. Allarity completed a Phase 3-ready stenoparib API manufacturing campaign ahead of schedule, with payments recorded as prepaid expenses. The company also obtained CLIA certification for its in-house DRP testing lab and reported Phase 2 data linking higher stenoparib DRP scores to extended overall survival in advanced ovarian cancer, while continuing FDA Fast Track-enabled ovarian and VA-funded SCLC Phase 2 trials.
Allarity Therapeutics (NASDAQ: ALLR) received a CLIA Certificate of Registration for its wholly owned laboratory in Horsholm, Denmark. This allows in-house DRP® testing to support U.S. clinical trials, including a planned pivotal stenoparib trial in advanced ovarian cancer.
The move is expected to reduce DRP® turnaround times, improve communication with trial sites, and create long-term cost savings. It also positions Allarity Therapeutics Medical Laboratory as a CLIA-certified partner for European biotech and pharma companies seeking U.S. trials or commercialization.
Allarity Therapeutics (NASDAQ: ALLR) announced that the USPTO has granted a key U.S. patent for its proprietary stenoparib DRP® companion diagnostic, with protection extending into April 2042.
The patent covers methods to predict benefit from stenoparib and select patients, supporting Allarity’s precision-medicine strategy in ovarian cancer and its long-term U.S. commercial exclusivity. Related DRP® patents run to 2039 in Europe and Australia.
Allarity Therapeutics (NASDAQ: ALLR) will present a Trial-in-Progress poster on its ongoing Phase 2 stenoparib (2X-121) study at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.
The trial evaluates stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer, building on prior Phase 2 experience and exploring a drug-specific DRP patient selection approach.
Allarity Therapeutics (NASDAQ: ALLR) reported first quarter 2026 results and progress for stenoparib across multiple cancers. Stenoparib development continued in advanced ovarian cancer under FDA Fast Track and in a VA-funded Phase 2 trial for relapsed small cell lung cancer.
The company received a USPTO Notice of Allowance for its stenoparib-specific DRP companion diagnostic, which, if issued as a patent, is expected to extend exclusivity by at least 11 years when used with the DRP. Stenoparib API manufacturing remains on track for completion in Q3 2026 with no additional cash outlays anticipated.
Allarity ended March 31, 2026 with $29.8 million in cash and restricted cash and closed a $20 million promissory note plus a $6 million equity line. Q1 2026 net loss was $2.75 million, or $0.17 per share, versus $2.73 million, or $0.25 per share, a year earlier.
Allarity Therapeutics (NASDAQ: ALLR) announced that CEO Thomas Jensen will speak at Precision Medicine Forum Europe 2026 in Stockholm on May 11, 2026 at 10:20–10:40 CEST. The presentation, “Dual Inhibition of PARP and WNT,” will cover stenoparib’s dual mechanism and the Stenoparib DRP® 414‑mRNA predictive biomarker, plus the company’s ongoing Phase 2 trials. Mr. Jensen will be available for individual meetings during the conference to discuss clinical development strategy and business development opportunities.